Compare HBB & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBB | ENGN |
|---|---|---|
| Founded | 1904 | 1999 |
| Country | United States | Canada |
| Employees | 660 | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.3M | 117.2M |
| IPO Year | 2017 | 2023 |
| Metric | HBB | ENGN |
|---|---|---|
| Price | $32.07 | $1.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $21.08 |
| AVG Volume (30 Days) | 69.0K | ★ 667.0K |
| Earning Date | 05-06-2026 | 06-11-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ 56.85 |
| EPS | ★ 2.75 | N/A |
| Revenue | ★ $606,852,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.52 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.56 | $1.40 |
| 52 Week High | $34.26 | $12.25 |
| Indicator | HBB | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.71 | 56.43 |
| Support Level | $29.49 | $1.67 |
| Resistance Level | $34.19 | $1.95 |
| Average True Range (ATR) | 1.30 | 0.07 |
| MACD | -0.16 | 0.01 |
| Stochastic Oscillator | 93.98 | 88.89 |
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.